Ascentage Pharma Group International
HKEX:6855

Watchlist Manager
Ascentage Pharma Group International Logo
Ascentage Pharma Group International
HKEX:6855
Watchlist
Price: 59.3 HKD -4.59% Market Closed
Market Cap: 22.1B HKD

Ascentage Pharma Group International
Depreciation & Amortization

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Ascentage Pharma Group International
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Ascentage Pharma Group International
HKEX:6855
Depreciation & Amortization
-Â¥80.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Depreciation & Amortization
-Â¥585.7m
CAGR 3-Years
-19%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Depreciation & Amortization
-Â¥2.4m
CAGR 3-Years
-25%
CAGR 5-Years
-86%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Depreciation & Amortization
-Â¥241.3m
CAGR 3-Years
-54%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ascentage Pharma Group International
Glance View

Market Cap
20.7B HKD
Industry
Biotechnology

Ascentage Pharma Group International, a biopharmaceutical company stepping confidently onto the global stage, is driven by a mission to address unmet medical needs in the challenging realm of apoptosis-targeted therapies. Founded in 2009, with roots in both China and the United States, the company has honed its expertise in developing innovative small-molecule therapeutics. Its focus is on diseases inadequately treated by current standards, particularly cancers, hepatitis B, and age-related diseases. By concentrating on inhibiting protein-protein interactions that govern apoptosis, Ascentage Pharma employs sophisticated science to guide its research and development programs. This strategic focus on apoptosis, the programmed cell death process, enables the company to work on promising drug candidates that specifically target the pathways responsible for the survival and proliferation of malignant cells. Revenue generation for Ascentage Pharma is multi-faceted. Primarily, the company earns through partnerships, milestone payments, collaborative agreements, and licensing deals with larger pharmaceutical firms eager to leverage its unique expertise in apoptosis. In addition, its robust pipeline—comprising compounds at various stages of clinical development—provides strategic opportunities for monetization through out-licensing agreements once promising clinical data is established. By creating a symbiotic relationship with its partners, while also advancing its proprietary drug candidates towards commercialization, Ascentage Pharma not only progresses its significant research but also solidifies its financial foundation. The company’s growth is anchored in its ability to translate groundbreaking science into viable treatments that can crucially impact patients’ lives, paving a path to sustained financial and innovative success.

Ascentage Pharma Group International Intrinsic Value
HIDDEN
Show

See Also

What is Ascentage Pharma Group International's Depreciation & Amortization?
Depreciation & Amortization
-80.3m CNY

Based on the financial report for Jun 30, 2025, Ascentage Pharma Group International's Depreciation & Amortization amounts to -80.3m CNY.

What is Ascentage Pharma Group International's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 1Y
-87%

Over the last year, the Depreciation & Amortization growth was -87%.

Back to Top